Friend, Brian D.
Muhsen, Ibrahim N. http://orcid.org/0000-0002-7156-2532
Patel, Shreeya
Hill, LaQuisa C. http://orcid.org/0000-0003-4304-935X
Lulla, Premal http://orcid.org/0000-0002-7707-2331
Ramos, Carlos A. http://orcid.org/0000-0002-4004-7837
Pingali, S. Ravi
Kamble, Rammurti T.
John, Tami D.
Salem, Baheyeldin
Bhar, Saleh
Doherty, Erin E.
Craddock, John
Sasa, Ghadir
Wu, Mengfen
Wang, Tao
Martinez, Caridad
Krance, Robert A.
Heslop, Helen E.
Carrum, George
Article History
Received: 7 October 2021
Revised: 20 January 2022
Accepted: 24 January 2022
First Online: 1 February 2022
Competing interests
: HEH is a current equity holder in Allovir, Marker Therapeutics; has been a member on a Board of Directors or advisory committee for Fresh Wind Biotherapies, Gilead, GlaxoSmithKline, Kiadis, Novartis, Takeda, Tessa Therapeutics; and has received research funding from Kuur Therapeutics and Tessa Therapeutics.